Uncategorized
Clearside to evaluate triamcinolone for macular edema in noninfectious uveitis in phase 2 trial
Clearside Biomedical has enrolled the first patient in a phase 2 clinical trial of its propriety formulation of triamcinolone acetonide for the treatment of macular edema associated with noninfectious uveitis, according to a press release.The randomized, controlled, masked, multicenter clinical trial will evaluate the safety and efficacy of triamcinolone acetonide administered through a suprachoroidal injection using a propriety microinjector.